Moderna Shares Drop 5.0%, Wiping Out $3.0 Billion as $2 Billion Convertible Notes Offering Challenges Cancer-Vaccine Surge
7 Articles
7 Articles
After the recent outbreak of its title, fuelled by the breakthrough towards a vaccine against skin cancer, biotechnology announced its intention to issue $2 billion in bonds convertible into shares.
Moderna Shares Drop 5.0%, Wiping Out $3.0 Billion as $2 Billion Convertible Notes Offering Challenges Cancer-Vaccine Surge
CAMBRIDGE, Massachusetts, August 27, 2026, 10:15 (EDT) Moderna (MRNA.O) stock slid 5.0% on Thursday, shaving $3.0 billion off its market value, after the company announced a $2 billion convertible notes sale, testing investor appetite following a recent rally in its cancer-vaccine business. Shares of Moderna declined 5.0% to $142.20 during Thursday morning trade.The firm put…
The US biotechnology laboratory Moderna has announced its intention to carry out, depending on market conditions and other factors, a private placement of $2 billion (€1,715 million) in convertible senior bonds with maturity in 2032 among "persons who are reasonably considered qualified institutional buyers".
Company has informed that it intends to use resources for general purposes, such as investments in the business of oncology and payment of debts
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
